Axon Enterprise (AXON) — Q2 2026 Earnings Preview

Report Date: Wednesday, August 5, 2026 (after market close) | Call: 2026Q2 Earnings Call

Setup Into the Print

AXON shares have been on a wild ride over the past year — from a 52-week high near $885 last August, down to a 52-week low of $339.01 on April 10, 2026, and now back up to roughly $607 heading into tomorrow's print, a gain of nearly 80% off the April trough. Momentum has been especially fierce in the last six weeks: shares have rallied from the mid-$400s in late June to the $600s now, driven by AI/counter-drone enthusiasm, a wave of institutional buying, and speculation around a large ICE Taser contract.

That rally means expectations are elevated. As one earnings preview put it, shares sit roughly 41% below their 52-week high of $885.92 despite a rally of nearly 30% over the past three months, trading at a market cap around $42 billion. The stock trades at over 200x earnings, meaning a merely "roughly in-line" quarter could read as a disappointment. This is a classic "priced for perfection" setup — Axon needs to keep beating and raising to justify the multiple.

Consensus Expectations for Q2 2026

Revenue: Consensus is clustered around $868M–$876M, implying roughly 30% year-over-year growth. The Zacks Consensus Estimate for second-quarter revenues is pegged at $868.4 million, indicating an increase of 29.9% from the year-ago quarter's figure.
EPS: Estimates vary by data provider between roughly $1.83 and $1.89 (non-GAAP). The consensus mark for earnings is pinned at $1.89 per share, which would represent a decline of 10.9% from the figure reported in the year-ago quarter — a reminder that comps get tougher as prior-year non-GAAP EPS included favorable items.
Segment expectations: The Zacks Consensus Estimate for the Connected Devices segment's revenue is pegged at $479 million, indicating a 27.4% increase year over year, while the Software & Services segment's net sales estimate is $390 million, a 33.6% year-over-year increase.
Beat history: Axon has been a serial "beat-and-raise" story — it has delivered four consecutive revenue beats, with Q4 FY2025 EPS coming in 34% above estimates (driving a +22.85% single-day gain) and Q2 FY2025 EPS beating by 45%. However, the company has topped the Zacks Consensus twice and missed twice in the preceding four quarters, with the most recent quarter (Q1) missing the EPS estimate by 3% — so the "always beats" narrative isn't perfectly clean, even though revenue beats have been consistent.

What Happened Last Quarter (Q1 2026 Recap — the Baseline)

Q1 set a high bar. Axon reported $807 million in revenue, up 34% year-over-year, its ninth consecutive quarter above 30% growth, with net income of $169 million (21% margin) and Adjusted EBITDA of $202 million (25% margin). Key growth engines:

AI Era Plan: AI product revenue grew over 700% year-over-year (off a small base), and AI bookings were up 140% YoY, with management noting that nearly all large domestic law enforcement agencies now include AI in their purchases.
Dedrone/counter-drone: Revenue up over 300% YoY, bookings up ~500% YoY — management called this "scaling beyond our most aggressive assumptions," deployed at the Super Bowl and Kentucky Derby, with the World Cup as an upcoming showcase.
International: Revenue more than doubled YoY and hit 20% of total revenue for a second straight quarter.
Enterprise: A $40 million deal with a major global telecom provider centered on Fusus, Axon Body Mini, and Outpost.
Backlog/ARR: Future contracted bookings rose 44% YoY to $14.3 billion; ARR grew 35% to $1.5 billion; net revenue retention held at 125%.

Management raised full-year 2026 revenue guidance to 30%–32% growth (from 27%–30%) while maintaining a 25.5% Adjusted EBITDA margin target, ~$450 million of free cash flow, and stock-based comp of $590M–$620M. Notably, Q1 free cash flow was an outflow of $55 million, driven by a deliberate, large inventory build (to hedge tariffs, memory costs, and component supply risk) — management has been explicit that this is a Q1 seasonal/strategic phenomenon and that FCF conversion should improve materially in the back half of the year.

Key Things to Watch on Tomorrow's Call

Does the guidance get raised again? Given the pattern of Q1's raise and the momentum in AI/Dedrone bookings, investors will be watching closely for another upward revision to the 30–32% revenue growth range or the 25.5% EBITDA margin target. A guide that merely reiterates prior guidance, without raising, given how much has already run up in the stock, could disappoint.
Bookings growth vs. revenue growth. Management has said bookings should grow roughly in line with revenue for the story to hold. Watch the bookings growth guidance closely — 39% bookings growth in recent quarters has been the leading indicator that revenue will continue to accelerate; a guide to +30% or above would likely confirm the bull case, while anything sub-25% could rattle the thesis.
Dedrone durability. Is counter-drone demand translating from "event-driven" (Super Bowl, Kentucky Derby, World Cup) into permanent infrastructure spend, as management has argued? Watch for updates on the Safer Skies Act ($250 million in federal grants for local counter-drone adoption) as a structural tailwind, and whether platform-solutions gross margin (historically the lowest-margin hardware bucket) is improving with scale.
AI product monetization. With Axon Vision, Guardian, and expanded Assistant capabilities rolling out through the second half (Vision GA targeted for early Q4), watch for updated AI bookings/revenue growth metrics and any commentary on cross-sell into enterprise, healthcare, and corrections verticals.
Gross margin trajectory. Q1 adjusted gross margin fell to 61.6% (down ~200bp YoY) on tariffs, memory costs, and Dedrone/services mix. Investors will want confirmation that this pressure is being managed and that the promised second-half operating leverage is materializing.
Free cash flow inflection. After the Q1 outflow tied to inventory investment, the market will want to see FCF turn decisively positive and stay on track for the ~$450 million full-year target, along with an update on net debt (was $1.0 billion as of March 31).
Federal/ICE contract commentary. This is a real wildcard. Axon is the incumbent on ICE's current Taser contract, worth about $16.1 million and set to expire August 21, 2026, and ICE has issued a request for information for a five-year, $220 million contract that would expand its Taser inventory from roughly 4,300 units to about 18,000. The specifications in ICE's document reportedly match only Axon's Taser 10, though no contract has been awarded. This has drawn political scrutiny given a Trump-linked account's disclosed purchase of Axon stock shortly before the solicitation surfaced, but a person familiar with the procurement said awarding of the contract appears to be stalled by its price tag and a shake-up in DHS leadership — so investors shouldn't assume near-term resolution, but any update on the call would be a notable catalyst either way.
Board refresh / strategic signal. Axon just added Vivek Mohindra, a former senior Dell Technologies executive, and Eiso Kant to its Board of Directors effective July 8, 2026, with Mohindra joining Audit and Compensation Committees. This looks like a deliberate move to deepen enterprise/AI-infrastructure expertise on the board — worth listening for any color on M&A appetite or enterprise-market strategy given Mohindra's Dell background and Kant's AI-venture pedigree.
Insider activity. CEO Patrick Smith sold shares in early July under a pre-arranged 10b5-1 plan, and another executive (Matthew McBrady) filed to sell roughly $600K in shares on August 4, right before earnings — routine under trading plans, but worth noting given the stock's run.

Bull Case vs. Bear Case Into the Print

Bull case: Axon is executing a genuine platform transformation — TASER/body-camera hardware is now a springboard into AI software (Axon Assistant past 1 million uses, Draft One, Vision, Guardian), counter-drone (Dedrone), real-time 911 operations (Carbyne/Prepared), and enterprise security (Fusus, Outpost). Backlog ($14.3B), ARR ($1.5B, +35%), and NRR (125%) all point to durable, compounding growth, and management has beaten and raised nearly every quarter for over two years.

Bear case: At roughly 200x+ trailing earnings and near all-time-high valuations, the stock is priced for flawless execution. Gross margins are under pressure from tariffs and mix shift toward lower-margin hardware (Dedrone, Platform Solutions); free cash flow has been volatile due to aggressive inventory building; and any deceleration in AI/Dedrone bookings growth, softer international lumpiness, or a weak guide could trigger an outsized negative reaction given how far and fast the stock has run since April.

Bottom Line

This print is less about whether Axon can deliver ~30% revenue growth (that's largely assumed) and more about whether bookings, margins, and the next leg of guidance confirm that the AI Era Plan, Dedrone, and enterprise/international expansion can sustain 30%+ growth into 2027 — and whether free cash flow inflects positively as promised. With the stock already up ~80% from its April low, the bar for a "good enough" quarter has risen considerably.